Q-omics provides the consensus-scored PMPCAP1 profile across patient tissues and cancer cell-line models. PMPCAP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, PMPCAP1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, PMPCAP1 RNA expression shows 8,270 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CHOL, KIRC, and TGCT as cancer lineages where PMPCAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMPCAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMPCAP1 survival associations across molecular data types. PMPCAP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMPCAP1 RNA expression–survival associations across cancer types. High PMPCAP1 expression shows unfavorable associations in CHOL, LUAD, THYM, LIHC and TGCT, but favorable associations in MESO. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for PMPCAP1 RNA expression.
This table summarizes PMPCAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PMPCAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMPCAP1 shows lower tumor expression in KIRC and THCA and higher tumor expression in COAD, LIHC, BRCA and PRAD. The KIRC box plot shows higher PMPCAP1 RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p = .004).
This table shows molecular features associated with PMPCAP1 in patient tissues and cancer cell lines. In patient samples, PMPCAP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
